Association ofFusobacterium nucleatuminfection with colorectal cancer in Chinese patients

Li, Yu Yuan; Ge, Quan Xing; Cao, Jie; Zhou, Yong; Du, Yongmei; Shen, Bo; Wan, Yu‐Jui Yvonne; Nie, Yu

doi:10.3748/wjg.v22.i11.3227

Cited by 148 publications

(126 citation statements)

References 38 publications

Supporting

Mentioning

121

Contrasting

Order By: Relevance

“…Thus far, the data as published by Li et al [33] do support our null hypothesis that an infection by Fusobacterium is a necessary and sufficient condition of colorectal carcinoma. In other words, without an infection by Fusobacterium no colorectal carcinoma and if an infection by Fusobacterium then colorectal carcinoma.…”

Section: Null Hypothesissupporting

confidence: 78%

“…The studies of Fukugaiti et al [31], Vogtmann et al [32] (two sided), Li et al [33], Amitay et al [34], Eklöf et al [35], where able to provide evidence that Fusobacterium is a necessary condition, a conditio sine qua non, of colon cancer. Con-sistent with this finding, the current study using data published by Ahn et al [30], Vogtmann et al [32] documented a significant cause effect relationship between Fusobacterium and colon cancer while the studies of Li et al [33], Amitay et al [34], Eklöf et al [35] were able to provide evidence of a highly significant cause effect relationship between Fusobacterium and colon cancer. In particular, we need to bear in mind that Li et al [33] were able within certain limits to provide evidence that Fusobacterium nucleatum is a necessary and sufficient condition of human colorectal cancer.…”

Section: Discussionmentioning

confidence: 97%

“…In this context, for example studies grounded on a sample size where the number of ((exposed to a specific risk factor) and (disease developed)) = ((not exposed to a specific risk factor) and (disease not developed)) will reduce the cost, speed up the development of drugs and are more appropriate in clinical trial studies or causal analysis. A simple, very impressive and preliminary example of such an approach is the Chinese study conducted by Li et al [33]. With these general considerations in place, let us examine once again the relationship between conditions and causes.…”

Section: Discussionmentioning

confidence: 99%

“…The data of Li et al [33] of an infection by Fusobacterium and colorectal cancer are viewed in the 2 × 2 table (Table 5). The X 2 Goodness-of-Fit Test with continuity correction of a necessary condition (conditio sine qua non) known to be defined as p (Fusobacterium ← Colorectal cancer) is calculated [36]- [54] as ( ) …”

Section: Proofmentioning

confidence: 99%

“…The data for this hypothesis test were provided by Li et al [33] and are illustrated in the 2 × 2 table (Table 5 …”

Section: Conditionsmentioning

confidence: 99%

See 4 more Smart Citations

Fusobacterium nucleatum—The Cause of Human Colorectal Cancer

Barukčić¹

2018

JBM

View full text Add to dashboard Cite

Objective: Accumulating evidence indicates that the gut microbiome has an increasingly important role in human disease and health. Fusobacterium nucleatum has been identified in several studies as the leading gut bacterium which is present in colorectal cancer (CRC). Still it is not clear if Fusobacterium plays a causal role. Methods: To explore the cause-effect relationship between Fusobacterium nucleatum and colorectal cancer, a systematic review and re-analysis of studies published were performed. The method of the conditio sine qua non relationship was used to proof the hypothesis without Fusobacterium nucleatum infection, no colorectal cancer. The mathematical formula of the causal relationship k was used to proof the hypothesis, whether there is a cause-effect relationship between Fusobacterium nucleatum and colorectal cancer. Significance was indicated by a p-value of less than 0.05. Result: The data analyzed support the Null-hypothesis that without Fusobacterium nucleatum infection, no colorectal cancer. In the same respect, the studies analyzed provide highly significant cause-effect relationship between Fusobacterium nucleatum and colorectal cancer. Conclusion: The findings of this study suggest that Fusobacterium (nucleatum) is the cause of colorectal cancer. KeywordsFusobacterium nucleatum, Human Colorectal Cancer, Causal Relationship IntroductionColorectal cancer has been ranked as the fourth most common cancer cause of death and the third most common cancer worldwide

show abstract

Section: Null Hypothesissupporting

confidence: 78%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Section: Proofmentioning

confidence: 99%

“…The data for this hypothesis test were provided by Li et al [33] and are illustrated in the 2 × 2 table (Table 5 …”

Section: Conditionsmentioning

confidence: 99%

See 3 more Smart Citations

Fusobacterium nucleatum—The Cause of Human Colorectal Cancer

Barukčić¹

2018

JBM

View full text Add to dashboard Cite

show abstract

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma

Witt,

Cass,

Tran

et al. 2023

JAMA Dermatol

View full text Add to dashboard Cite

ImportanceThe gut microbiome modulates the immune system and responses to immunotherapy in patients with late-stage melanoma. It is unknown whether fecal microbiota profiles differ between healthy individuals and patients with melanoma or if microbiota profiles differ among patients with different stages of melanoma. Defining gut microbiota profiles in individuals without melanoma and those with early-stage and late-stage melanoma may reveal features associated with disease progression.ObjectiveTo characterize and compare gut microbiota profiles between healthy volunteers and patients with melanoma and between patients with early-stage and late-stage melanoma.Design, Setting, and ParticipantsThis single-site case-control study took place at an academic comprehensive cancer center. Fecal samples were collected from systemic treatment−naive patients with stage I to IV melanoma from June 1, 2015, to January 31, 2019, and from healthy volunteers from June 1, 2021, to January 31, 2022. Patients were followed up for disease recurrence until November 30, 2021.Main Outcomes and MeasuresFecal microbiota was profiled by 16S ribosomal RNA sequencing. Clinical and pathologic characteristics, treatment, and disease recurrence were extracted from electronic medical records. Fecal microbiome diversity, taxonomic profiles and inferred functional profiles were compared between groups.ResultsA total of 228 participants were enrolled (126 men [55.3%]; median age, 59 [range, 21-90] years), including 49 volunteers without melanoma, 38 patients with early-stage melanoma (29 with stage I or melanoma in situ and 9 with stage II), and 141 with late-stage melanoma (66 with stage III and 75 with stage IV). Community differences were observed between patients with melanoma and volunteers. Patients with melanoma had a higher relative abundance of Fusobacterium compared with controls on univariate analysis (0.19% vs 0.003%; P &lt; .001), but this association was attenuated when adjusted for covariates (log2 fold change of 5.18 vs controls; P = .09). Microbiomes were distinct between patients with early-stage and late-stage melanoma. Early-stage melanoma had a higher alpha diversity (Inverse Simpson Index 14.6 [IQR, 9.8-23.0] vs 10.8 [IQR, 7.2-16.8]; P = .003), and a higher abundance of the genus Roseburia on univariate analysis (2.4% vs 1.2%; P &lt; .001) though statistical significance was lost with covariate adjustment (log2 fold change of 0.86 vs controls; P = .13). Multiple functional pathways were differentially enriched between groups. No associations were observed between the microbial taxa and disease recurrence in patients with stage III melanoma treated with adjuvant immunotherapy.Conclusions and RelevanceThe findings of this case-control study suggest that fecal microbiota profiles were significantly different among patients with melanoma and controls and between patients with early-stage and late-stage melanoma. Prospective investigations of the gut microbiome and changes that occur with disease progression may identify future microbial targets for intervention.

show abstract

Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis

et al. 2018

View full text Add to dashboard Cite

The development and progression of colorectal cancer (CRC) is closely related to gut microbiome. Here we investigated the impact of lipopolysaccharide (LPS), one of the most prevalent products in the gut microbiome, on CRC immunotherapy. We found that LPS was abundant in orthotopic CRC tissue and was associated with low responses to anti-PD-L1 mAb therapy, and clearance of Gram-negative bacteria from the gut using polymyxin B (PmB), or blockade of Toll-like receptor 4 using TAK-242, would both relieve the immunosuppressive microenvironment and boost T-cell infiltration into the CRC tumor. Further, we designed an engineered LPS-targeting fusion protein and loaded its coding sequence into a lipid-protamine-DNA (LPD) nanoparticle system for selectively expression of LPS trap protein and blocking LPS inside the tumor, and this nano-trapping system significantly relieved the immunosuppressive microenvironment and boosted anti-PD-L1 mAb therapy against CRC tumor. This LPS trap system even attenuated CRC liver metastasis when applied, suggesting the importance of blocking LPS in the gut-liver axis. The strategy applied here may provide a useful new way for treating CRC as well as other epithelial cancers that interact with mucosa microbiome.

show abstract

Association ofFusobacterium nucleatuminfection with colorectal cancer in Chinese patients

Abstract: F. nucleatum was enriched in CRC tissues and associated with CRC development and metastasis.

Cited by 148 publications

References 38 publications

<i>Fusobacterium nucleatum</i>—The Cause of Human Colorectal Cancer

<i>Fusobacterium nucleatum</i>—The Cause of Human Colorectal Cancer

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma

Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis

Contact Info

Product

Resources

About

Association ofFusobacterium nucleatuminfection with colorectal cancer in Chinese patients

Abstract: F. nucleatum was enriched in CRC tissues and associated with CRC development and metastasis.

Cited by 148 publications

References 38 publications

&lt;i&gt;Fusobacterium nucleatum&lt;/i&gt;—The Cause of Human Colorectal Cancer

&lt;i&gt;Fusobacterium nucleatum&lt;/i&gt;—The Cause of Human Colorectal Cancer

Gut Microbiome in Patients With Early-Stage and Late-Stage Melanoma

Trapping of Lipopolysaccharide to Promote Immunotherapy against Colorectal Cancer and Attenuate Liver Metastasis

Contact Info

Product

Resources

About

<i>Fusobacterium nucleatum</i>—The Cause of Human Colorectal Cancer

<i>Fusobacterium nucleatum</i>—The Cause of Human Colorectal Cancer